Alyeska Investment Group L.P. Increases Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Alyeska Investment Group L.P. grew its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 903.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,253,724 shares of the company's stock after purchasing an additional 1,128,724 shares during the period. Alyeska Investment Group L.P. owned about 1.29% of ARS Pharmaceuticals worth $13,227,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in shares of ARS Pharmaceuticals by 93.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company's stock worth $3,631,000 after buying an additional 165,950 shares in the last quarter. Wells Fargo & Company MN boosted its position in ARS Pharmaceuticals by 47.1% in the fourth quarter. Wells Fargo & Company MN now owns 41,701 shares of the company's stock worth $440,000 after purchasing an additional 13,361 shares during the last quarter. Peregrine Capital Management LLC bought a new position in ARS Pharmaceuticals in the 4th quarter valued at $4,469,000. Vanguard Group Inc. increased its position in shares of ARS Pharmaceuticals by 3.5% during the 4th quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company's stock valued at $36,555,000 after purchasing an additional 115,656 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of ARS Pharmaceuticals by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company's stock worth $4,510,000 after purchasing an additional 3,530 shares during the period. 68.16% of the stock is owned by institutional investors.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, Director Laura Shawver sold 49,600 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the transaction, the director now directly owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This trade represents a 19.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Karas sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares of the company's stock, valued at approximately $107,744. This represents a 56.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,602 shares of company stock worth $1,311,041 over the last 90 days. Corporate insiders own 40.10% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on SPRY. Raymond James raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 14th. Oppenheimer began coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an "outperform" rating and a $40.00 price objective for the company. Scotiabank started coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 target price on the stock. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Leerink Partners upped their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ARS Pharmaceuticals presently has an average rating of "Buy" and an average price target of $31.00.

ARS Pharmaceuticals Price Performance

SPRY stock traded down $0.05 during mid-day trading on Friday, reaching $13.44. 1,043,318 shares of the company traded hands, compared to its average volume of 1,188,568. ARS Pharmaceuticals, Inc. has a 52-week low of $7.55 and a 52-week high of $18.51. The company has a market capitalization of $1.32 billion, a P/E ratio of -26.35 and a beta of 0.84. The company has a fifty day moving average price of $13.09 and a 200-day moving average price of $12.99.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.56. The firm had revenue of $86.58 million during the quarter, compared to analysts' expectations of $15.46 million. As a group, analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.